## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.7% below STRENGTH zone (3.0-6.0%); PEG 4.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($674.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?**
- Source: The Globe and Mail | 20251204T175458 | Bullish | Relevance: 99%
-  IDEXX Laboratories (IDXX) has seen its stock rally 75.6% year-to-date, significantly outperforming its industry and the S&P 500, driven by strong strategic execution, new business gains, and high customer retention. The surge is primarily attributed to robust momentum in its Companion Animal Group (CAG) Diagnostics business, which has shown consistent recurring revenue growth above sector levels and benefited from increased test volumes and an expanding installed base of premium instruments. The company's cloud-based products and pet owner engagement application, Vello, are also key growth drivers, despite concerns about global macroeconomic conditions and currency fluctuations.

**2. How Is IDEXX Laboratoriesâ€™ Stock Performance Compared to Other Health Care Stocks?**
- Source: Markets Financial Content | 20251204T022900 | Bullish | Relevance: 99%
-  IDEXX Laboratories (IDXX) is a global leader in veterinary diagnostics, consistently outperforming the Health Care Select Sector SPDR Fund (XLV) and rival Zoetis Inc. (ZTS) over several periods. The company's strong performance is driven by a diversified product ecosystem, recurring revenue model, and robust R&D, leading to increased full-year guidance and a "Moderate Buy" consensus rating from analysts.

**3. IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?**
- Source: Eastern Progress | 20251204T190752 | Bullish | Relevance: 99%
- IDEXX Laboratories (IDXX) stock has rallied 75.6% year-to-date, outperforming its industry and the S&P 500, driven by strong strategic execution, new business gains, and high customer retention. The company's Companion Animal Group Diagnostics segment shows particular strength, with recurring revenue growth exceeding sector levels both domestically and internationally. Cloud-based products and an expanding pet owner engagement application are also contributing significantly to its growth.

**4. Arrowstreet Capital Limited Partnership Acquires 15,227 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251204T090925 | Somewhat-Bullish | Relevance: 99%
-  Arrowstreet Capital Limited Partnership increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.0%, acquiring an additional 15,227 shares to hold a total of 206,137 shares valued at $110.56 million. This comes as analysts have raised price targets for IDEXX, with a consensus of "Moderate Buy" and an average target price of $730.50. Meanwhile, insider activity shows EVP Nimrata Hunt selling 9,425 shares, reducing her ownership by over 30%.

**5. Epoch Investment Partners Inc. Has $134.40 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251205T100357 | Somewhat-Bullish | Relevance: 98%
-  Epoch Investment Partners Inc. significantly increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 24.7% in the second quarter, valuing its holdings at approximately $134.40 million. Other institutional investors also adjusted their positions in the company, which currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $730.50. The article also details recent financial performance, including a Q3 EPS beat and a 13.3% year-over-year revenue increase, alongside an insider stock sale by EVP Nimrata Hunt.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.2x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.22 signals overvaluation risk, limited margin of safety. Forward P/E 49.5x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.9B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.22 |
| Forward P/E | 49.5 |
| Current P/E | 55.3 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.0% to -4.7% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.28x) but short-term weakness (below SMA20). MACD histogram bearish (-3.24), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.74% (CS: 8) | Weak |
| RSI_14 | 52.5 | Neutral |
| MACD Histogram | -3.24 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.060x | Above |
| vs SMA200 | 1.277x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $714.10
- **Stop Loss:** $674.36 (5.6% risk)
- **Target:** $753.84 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $8,569.20
- **Portfolio %:** 8.57%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*